INO / Inovio Pharmaceuticals, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Inovio Pharmaceuticals, Inc. Amended and Restated 2023 Omnibus Incentive Plan

Exhibit 10.1 INOVIO PHARMACEUTICALS, INC. AMENDED AND RESTATED 2023 OMNIBUS INCENTIVE PLAN Adopted by the Board of Directors: February 27, 2025 Approved by Stockholders: May 20, 2025 Inovio Pharmaceuticals, Inc. Amended and Restated 2023 Omnibus Incentive Plan 1.General. (a)Prior Plan. The Company originally adopted the Inovio Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan effective as of the O

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, I

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Exhibit 99.1 INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights •On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end •Completed design verification (DV) testing of CELLECTRA® 5PSP device required for BLA submission and requested rolling submission from US Food and Drug Administration (FDA) •Conti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Inovio Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Inovio Pharmaceuticals, Inc.

Underwriting Agreement, dated July 2, 2025, by and between Inovio Pharmaceuticals, Inc. and Piper Sandler & Co.

EX-1.1 Exhibit 1.1 INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 14,285,715 Shares of Common Stock Series A Warrants to Purchase Up to 14,285,715 Shares of Common Stock (or Pre-Funded Warrants in lieu thereof) Series B Warrants to Purchase Up to 14,285,715 Shares of Common Stock (or Pre-Funded Warrants in lieu thereof) UNDERWRITING AGREEMENT Dated: July 2, 2025 INOVIO PHARMACEUTICALS, INC.

Form of Series B Warrant.

EX-4.3 Exhibit 4.3 WARRANT TO PURCHASE COMMON STOCK INOVIO PHARMACEUTICALS, INC. Warrant Shares: [ ] Issue Date: July 7, 2025 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date

Form of Pre-Funded Warrant.

EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT INOVIO PHARMACEUTICALS, INC. Warrant Shares: Date of Issuance: July 7, 2025 (such date, the “Issue Date”) Warrant No.: PF-[    ] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitati

Form of Series A Warrant.

EX-4.2 Exhibit 4.2 WARRANT TO PURCHASE COMMON STOCK INOVIO PHARMACEUTICALS, INC. Warrant Shares: [  ] Issue Date: July 7, 2025 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Dat

INOVIO Announces Pricing of $25 Million Public Offering

Exhibit 99.2 INOVIO Announces Pricing of $25 Million Public Offering PLYMOUTH MEETING, PA – July 2, 2025 /PRNewswire/ – INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2025 Inovio Pharmaceuticals

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2025 Inovio Pharmaceuticals, Inc.

INOVIO Announces Proposed Public Offering

EX-99.1 Exhibit 99.1 INOVIO Announces Proposed Public Offering PLYMOUTH MEETING, PA – July 2, 2025 /PRNewswire/ – INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its commo

Bookrunning Manager Piper Sandler Passive Bookrunner Oppenheimer & Co. The date of this prospectus supplement is July 2, 2025.

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-275445 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 31, 2024) 14,285,715 Shares of Common Stock Series A Warrants to Purchase up to 14,285,715 Shares of Common Stock (or Pre-Funded Warrants) Series B Warrants to Purchase up to 14,285,715 Shares of Common Stock (or Pre-Funded Warrants) We are offering 14,285,715 shares of our common stock, par value $0.

The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospect

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-275445 The information in this preliminary prospectus supplement is not complete and may be changed.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 Inovio Pharmaceuticals

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 Inovio Pharmaceuticals, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Inovio Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS,

INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights

Exhibit 99.1 INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights •On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025 ◦Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC.

Insider Trading Policy (filed herewith)

Exhibit 19.1 Insider Trading Policy Amended and Restated on May 16, 2023 MEMORANDUM TO: All Company Personnel FROM: Inovio Pharmaceuticals, Inc. DATE: May 16, 2023 (Amended and Restated) RE: Compliance with the Company’s Insider Trading Policy As a director, officer, employee, consultant or contractor of Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), your ability to purchase

INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Exhibit 99.1 INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights •Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) –Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed

Subsidiaries of the registrant (filed herewith).

Exhibit 21.1 INOVIO PHARMACEUTICALS, INC. Subsidiaries Subsidiary Name(1) Jurisdiction of Organization Inovio Asia, LLC South Korea

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 Inovio Pharmaceuticals, Inc.

AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G

EXHIBIT 99 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer.

Form of Warrant.

Exhibit 4.1 WARRANT TO PURCHASE COMMON STOCK INOVIO PHARMACEUTICALS, INC. Warrant Shares: [  ]           Issue Date: December 16, 2024 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the I

Underwriting Agreement, dated December 12, 2024, by and among Inovio Pharmaceuticals, Inc., Oppenheimer & Co. Inc. and Citizens JMP Securities LLC.

Exhibit 1.1 INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 10,000,000 Shares of Common Stock Warrants to Purchase Up to 10,000,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: December 12, 2024 INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 10,000,000 Shares of Common Stock Warrants to Purchase Up to 10,000,000 Shares of Common Stock UNDERWRITING AGREEMENT December 12, 2024 O

INOVIO Announces Pricing of $30 Million Public Offering

Exhibit 99.1 INOVIO Announces Pricing of $30 Million Public Offering PLYMOUTH MEETING, PA – December 13, 2024 /PRNewswire/ – INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 Inovio Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 Inovio Pharmaceuticals, Inc.

10,000,000 shares of common stock Warrants to purchase 10,000,000 shares of common stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-275445 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 31, 2024) 10,000,000 shares of common stock Warrants to purchase 10,000,000 shares of common stock We are offering 10,000,000 shares of our common stock, par value $0.

The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospect

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-275445 The information in this preliminary prospectus supplement is not complete and may be changed.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Inovio Pharmaceuticals, Inc.

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Exhibit 99.1 INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights –New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences •Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma •Data sho

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Inovio Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Inovio Pharmaceuticals, Inc.

Equity Distribution Agreement, dated August 13, 2024, by and between Inovio Pharmaceuticals, Inc. and Oppenheimer & Co. Inc.

Exhibit 1.1 Inovio Pharmaceuticals, Inc. Common Stock, $0.001 par value EQUITY DISTRIBUTION AGREEMENT August 13, 2024 Oppenheimer & Co. Inc. 85 Broad Street New York, New York 10004 Ladies and Gentlemen: Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Oppenheimer & Co. Inc

Up to $60,000,000 Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-275445 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 31, 2024) Up to $60,000,000 Common Stock We have entered into an Equity Distribution Agreement, or the Sales Agreement, with Oppenheimer & Co.

INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Exhibit 99.1 INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights PLYMOUTH MEETING, PA – August 8, 2024 – INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, I

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Inovio Pharmaceuticals, Inc.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 Inovio Pharmaceuticals, Inc.

INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights

Exhibit 99.1 INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights • BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papillomatosis (RRP) • Planning initiation of confirmatory trial for INO-3107 based on FDA feedback • Advancing plans for Phase 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Inovio Pharmaceuticals

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Inovio Pharmaceuticals, Inc.

INO / Inovio Pharmaceuticals, Inc. / Deep Track Capital, LP Passive Investment

SC 13G 1 deeptrack-ino041624.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* INOVIO PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 45773H409 (CUSIP Number) April 16, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat

Form of Pre-Funded Warrant.

EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT INOVIO PHARMACEUTICALS, INC. Warrant Shares:     Date of Issuance:    , 2024 (such date, the “Issue Date”) Warrant No.: PF-[    ] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 Inovio Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 Inovio Pharmaceuticals, Inc.

Underwriting Agreement, dated April 15, 2024, by and among Inovio Pharmaceuticals, Inc., Oppenheimer & Co. Inc. and Citizens JMP Securities, LLC.

Exhibit 1.1 INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 2,536,258 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 2,135,477 Shares of Common Stock UNDERWRITING AGREEMENT Dated: April 15, 2024 INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 2,536,258 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 2,135,477 Shares of Common Stock UNDERWRITING AGREEMENT Apri

INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

EX-99.1 Exhibit 99.1 INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants PLYMOUTH MEETING, Pa., April 15, 2024 /PRNewswire/ — INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious dis

2,536,258 shares of common stock Pre-funded warrants to purchase up to 2,135,477 shares of common stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-275445 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 31, 2024) 2,536,258 shares of common stock Pre-funded warrants to purchase up to 2,135,477 shares of common stock We are offering 2,536,258 shares of our common stock, par value $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

Subsidiaries of the registrant (filed herewith).

Exhibit 21.1 INOVIO PHARMACEUTICALS, INC. Subsidiaries Subsidiary Name(1) Jurisdiction of Organization Inovio Asia, LLC South Korea

Participation Agreement under Severance Plan for Jacqueline Shea (filed herewith).

Exhibit 10.18 Appendix A INOVIO PHARMACEUTICALS, INC. SEVERANCE PLAN Participation Agreement Inovio Pharmaceuticals, Inc. (the “Company”) is pleased to inform you, Jacqueline E. Shea, that you have been selected to participate in the Company’s Severance Plan (the “Plan”) as a Covered Employee. A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC.

Inovio Pharmaceuticals, Inc. Severance Plan and Summary Plan Description (filed herewith).

Exhibit 10.17 INOVIO PHARMACEUTICALS, INC. SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION APPROVED BY THE BOARD OF DIRECTORS: 1.Introduction. The purpose of this Inovio Pharmaceuticals, Inc. Severance Plan (the “Plan”) is to provide specified severance benefits to eligible executives of the Company (as defined below) whose employment is terminated by the Company or a successor under certain circumsta

First Amendment to the Amended and Restated License and Collaboration Agreement, dated June 14, 2023, by and between Inovio Pharmaceuticals, Inc. and Beijing Apollo Saturn Biological Technology Limited (filed herewith).

Exhibit 10.11 FIRST AMENDMENT TO THE AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT This First Amendment to the Amended and Restated License and Collaboration Agreement (this “First Amendment”), dated as of June 14, 2023 (the “First Amendment Date”), is entered into by and between Beijing Apollo Saturn Biological Technology Limited, a People’s Republic of China corporation having a princ

Participation Agreement under Severance Plan for Michael Sumner (filed herewith).

Exhibit 10.20 Appendix A INOVIO PHARMACEUTICALS, INC. SEVERANCE PLAN Participation Agreement Inovio Pharmaceuticals, Inc. (the “Company”) is pleased to inform you, Michael Sumner, that you have been selected to participate in the Company’s Severance Plan (the “Plan”) as a Covered Employee. A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan is

Incentive Compensation Recoupment Policy, adopted on November 14, 2023 (filed herewith)

Exhibit 97.1 INOVIO PHARMACEUTICALS, INC. Incentive Compensation Recoupment Policy 1.Introduction The Board of Directors (the “Board”) of Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupmen

Participation Agreement under Severance Plan for Laurent Humeau (filed herewith).

Exhibit 10.19 Appendix A INOVIO PHARMACEUTICALS, INC. SEVERANCE PLAN Participation Agreement Inovio Pharmaceuticals, Inc. (the “Company”) is pleased to inform you, Laurent M. Humeau, that you have been selected to participate in the Company’s Severance Plan (the “Plan”) as a Covered Employee. A copy of the Plan was delivered to you with this Participation Agreement. Your participation in the Plan

INO / Inovio Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01190-inoviopharmaceutical.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Inovio Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 45773H201 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box

January 29, 2024

January 29, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.

As filed with the Securities and Exchange Commission on January 26, 2024

As filed with the Securities and Exchange Commission on January 26, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Inovio Pharmaceuticals, Inc.

Certificate of Amendment to Certificate of Incorporation, effective as of January 24, 2024 (incorporated by reference to Exhibit 3.1 to the registrant’s current report on Form 8-K filed on January 25, 2024).

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF INOVIO PHARMACEUTICALS, INC. Inovio Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), hereby certifies that: FIRST: The name of this Company is Inovio Pharmaceuticals, Inc. SECOND: The original name of the Company was “Ge

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2024 Inovio Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2024 Inovio Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2024 Inovio Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2024 Inovio Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights

Exhibit 99.1 INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights • Achieved significant progress with lead product candidate, INO-3107 • Received Breakthrough Therapy designation from U.S. Food and Drug Administration (FDA) as a potential treatment for Recurrent Respiratory Papillomatosis (RRP) • Received FDA feedback that data from completed Phase 1/2 trial could be use

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICA

Form of Common Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.7 INOVIO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF INOVIO PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between INOVIO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.8 INOVIO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF INOVIO PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between INOVIO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] o

Form of Debt Securities Warrant Agreement and Warrant Certificate.

Exhibit 4.9 INOVIO PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF INOVIO PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between INOVIO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] o

Form of Indenture, between the registrant and one or more trustees to be named.

Exhibit 4.5 INOVIO PHARMACEUTICALS, INC, Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1  DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2  ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Inovio Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Inovio Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Inovio Pharmaceuticals, Inc.

As filed with the Securities and Exchange Commission on November 9, 2023

Table of Contents As filed with the Securities and Exchange Commission on November 9, 2023 Registration No.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 Inovio Pharmaceuticals, Inc.

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program

EX-99.1 Exhibit 99.1 INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program – Previously planned Phase 3 trial no longer required to support Biological License Application (BLA) submission – If approved, INO-3107 could potentially revolutionize treatment options for patients with Recurrent Respiratory Papillo

Regulation FD Disclosure, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 Inovio Pharmaceuticals, Inc.

Form of Option Grant Package under 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.2 to the registrant’s quarterly report on Form 10-Q filed on August 9, 2023).

Exhibit 10.2 Inovio Pharmaceuticals, Inc. Stock Option Grant Notice (2023 Omnibus Incentive Plan) Inovio Pharmaceuticals, Inc. (the “Company”) (the “Company”), pursuant to the Company’s 2023 Omnibus Incentive Plan (the “Plan”), has granted to you (“You,” or “Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all o

Form of RSU Grant Package under 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.3 to the registrant’s quarterly report on Form 10-Q filed on August 9, 2023).

Exhibit 10.3 Inovio Pharmaceuticals, Inc. RSU Award Grant Notice (2023 Omnibus Incentive Plan) Inovio Pharmaceuticals, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2023 Omnibus Incenti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Inovio Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Inovio Pharmaceuticals, Inc.

INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Commi

Exhibit 99.1 INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Commission in second quarter Scaling resources and headcount to align with strategic focus on INO-3107 and late-stage clinical candidates clos

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 Inovio Pharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 Inovio Pharmaceuticals, Inc.

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA IN RE INOVIO PHARMACEUTICALS, INC. DERIVATIVE LITIGATION Lead Case No. 2:20-cv-01962-GJP STIPULATION AND AGREEMENT OF SETTLEMENT

EX-99.1 Exhibit 99.1 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA IN RE INOVIO PHARMACEUTICALS, INC. DERIVATIVE LITIGATION Lead Case No. 2:20-cv-01962-GJP STIPULATION AND AGREEMENT OF SETTLEMENT This Stipulation and Agreement of Settlement (the “Stipulation”) is made and entered into by the following parties, each by and through their respective counsel: (1) plaintiffs Pedram Behe

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA IN RE INOVIO PHARMACEUTICALS, INC. DERIVATIVE LITIGATION Lead Case No. 2:20-cv-01962-GJP NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE ACTIONS

EX-99.2 Exhibit 99.2 INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions PLYMOUTH MEETING, PA., June 23, 2023 — INOVIO (NASDAQ: INO) has released the following pursuant to an order of the UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA: UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA IN RE INOVIO PHARMACEUTICALS, INC. DERIVATIVE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 Inovio Pharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 Inovio Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Inovio Pharmaceuticals

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Inovio Pharmaceuticals, Inc.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 INOVIO PHARMACEUTICALS, INC.

As filed with the Securities and Exchange Commission on May 18, 2023

S-8 As filed with the Securities and Exchange Commission on May 18, 2023 Registration No.

As filed with the Securities and Exchange Commission on May 18, 2023

S-8 As filed with the Securities and Exchange Commission on May 18, 2023 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 INOVIO PHARMACEUTICALS, INC.

Inovio Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the registrant’s current report on Form 8-K filed on May 18, 2023).

EX-10.1 Exhibit 10.1 INOVIO PHARMACEUTICALS, INC. 2023 OMNIBUS INCENTIVE PLAN Adopted by the Board of Directors: March 24, 2023 Approved by Stockholders: May 16, 2023 INOVIO PHARMACEUTICALS, INC. 2023 OMNIBUS INCENTIVE PLAN 1. GENERAL. (a) Prior Plan. As of May 16, 2023, no additional awards may be granted under the Prior Plan. All awards granted under the Prior Plan will remain subject to the ter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Inovio Pharmaceuticals

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Inovio Pharmaceuticals, Inc.

INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights

EX-99.1 Exhibit 99.1 INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights • Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients • Second cohort of trial showed 10 of the 11 (91%) patients saw a reduction in surgical interventions in the year following initial treatment • New combined safety and immunologica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

As filed with the Securities and Exchange Commission on March 28, 2023

POS EX As filed with the Securities and Exchange Commission on March 28, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

Filing Fee Table (incorporated by reference to Exhibit 107 to the registrant’s Post-Effective Amendment No. 1 to Form S-3 filed with the SEC on March 1, 2023)

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment to Form S-3 (Form Type) Inovio Pharmaceuticals, Inc.

As filed with the Securities and Exchange Commission on March 1, 2023

POS AM As filed with the Securities and Exchange Commission on March 1, 2023 Registration No.

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 Inovio Pharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 Inovio Pharmaceuticals, Inc.

As filed with the Securities and Exchange Commission on March 1, 2023

POSASR Table of Contents As filed with the Securities and Exchange Commission on March 1, 2023 Registration No.

Subsidiaries of the registrant (filed herewith).

Exhibit 21.1 INOVIO PHARMACEUTICALS, INC. Subsidiaries Subsidiary Name(1) Jurisdiction of Organization Inovio Asia, LLC South Korea

INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights

EX-99.1 Exhibit 99.1 INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights • Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions (HSIL) • Trial results did not meet the primary endpoint in the biomarker-selected population • Trial results did achieve statist

INO / Inovio Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01150-inoviopharmaceutical.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Inovio Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 45773H201 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate bo

INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates

EX-99.1 Exhibit 99.1 INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates • Cost-saving measures include 11% headcount reduction • Annual savings expected to be approximately $4.3 million • Data readouts expected in first quarter of 2023 for key programs including INO-3107 for RRP and VGX-3100 for cervical HSIL PLYMOUTH MEETING, PA, January 31,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 Inovio Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 Inovio Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICA

INOVIO Pharmaceuticals, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2022 December 31, 2021 ASSETS Current assets: Cash and cash equivalents $ 21,988,239 $ 71,143,778 Short-term investments 259,894,898 330,170,940 Accounts receivable 2,44

EX-99.1 Exhibit 99.1 INOVIO Reports Financial Results and Highlights for the Third Quarter 2022 • Announced positive interim data for INO-3107 as a potential first-in-class treatment for Recurrent Respiratory Papillomatosis • Advanced strategy to focus on developing candidates that have the greatest opportunity for near-term success • Updates prior financial guidance and extends cash runway into f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Inovio Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Inovio Pharmaceuticals, Inc.

Cooley LLP Reston Town Center 11951 Freedom Drive 14th Floor Reston, VA 20190-5656 t: +1 703 456 8000 f: +1 703 456 8100 cooley.com

Brian F. Leaf T: +1 703 456 8053 [email protected] VIA EDGAR September 29, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Jenn Do Christine Torney Re: Inovio Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2021 Filed March 1, 2022 File No. 001-14888 Dear Ms. Do and Ms. Torney:

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Inovio Pharmaceuticals, Inc.

INOVIO Reports Financial Results and Highlights for the Second Quarter 2022

Exhibit 99.1 INOVIO Reports Financial Results and Highlights for the Second Quarter 2022 ? Increased Cash Runway into Third Quarter 2024 with Cost-Savings and Corporate Restructuring Efforts ? Strengthened Executive Team with Appointment of Dr. Michael Sumner as Chief Medical Officer ? Announced Positive Data from a Phase 1/2 Trial with INO-5401 to treat Glioblastoma (GBM) at the American Society

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, I

of the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2022 filed on August 9, 2022

Exhibit 10.1 May 9, 2022 Dr. J. Joseph Kim Re: Separation Agreement Dear Joseph: This letter sets forth the substance of the separation agreement (the ?Agreement?) which Inovio Pharmaceuticals, Inc. (the ?Company?) and you have agreed to in connection with your cessation of employment. 1.Separation. You and the Company have mutually agreed that your employment with the Company will end on May 10,

Regulation FD Disclosure, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2022 Inovio Pharmaceuticals, Inc.

INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients

Exhibit 99.1 INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients ? Changes expected to reduce operational expenses and extend the company?s cash runway into third quarter of 2024 ? Improving cost structure will allow company to focus on strategic priorities, including heterologous boost strategy for C

Powers of Attorney (included on signature page).

As filed with the Securities and Exchange Commission on June 30, 2022 Registration No.

Form of RSU Grant Package under 2022 Inducement Plan (incorporated by reference to Exhibit 99.3 of the registrant’s Form S-8 registration statement, filed on June 30, 2022).

Exhibit 99.3 INOVIO PHARMACEUTICALS, INC. RSU AWARD GRANT NOTICE (2022 INDUCEMENT PLAN) Inovio Pharmaceuticals, Inc. (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified and on the terms set forth below (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company?s 2022 Inducement Plan (the ?

Inovio Pharmaceuticals, Inc. 2022 Inducement Plan (incorporated by reference to Exhibit 99.1 of the registrant’s Form S-8 registration statement, filed on June 30, 2022).

Exhibit 99.1 INOVIO PHARMACEUTICALS, INC. 2022 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: JUNE 24, 2022 TABLE OF CONTENTS Page 1. GENERAL. 1 2. SHARES SUBJECT TO THE PLAN. 1 3. ELIGIBILITY AND LIMITATIONS. 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS. 2 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS. 6 6. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS. 8 7. ADMI

Form of Option Grant Package under 2022 Inducement Plan (incorporated by reference to Exhibit 99.2 of the registrant’s Form S-8 registration statement, filed on June 30, 2022).

Exhibit 99.2 INOVIO PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2022 INDUCEMENT PLAN) Inovio Pharmaceuticals, Inc. (the ?Company?) (the ?Company?), pursuant to the Company?s 2022 Inducement Plan (the ?Plan?), has granted to you (?You,? or ?Optionholder?) an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). Your Option is subject to all of the terms an

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 INOVIO PHARMACEUTICALS, INC.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 Inovio Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

INOVIO Reports First Quarter 2022 Financial Results and Program Developments

Exhibit 99.1 INOVIO Reports First Quarter 2022 Financial Results and Program Developments ? Announces prioritization of heterologous booster strategy for COVID-19 vaccine candidate INO-4800 and discontinuation of Phase 3 INNOVATE trial to optimize potential impact on global public health ? Reports, with partner Advaccine, positive T cell immune response data with INO-4800 as a heterologous booster

INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer Dr. Shea brings more than 25 years of leadership and industry expertise in life sciences and biotech

Exhibit 99.2 INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer Dr. Shea brings more than 25 years of leadership and industry expertise in life sciences and biotech PLYMOUTH MEETING, PA ? May 10, 2022 ? INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat pe

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Inovio Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS,

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

As filed with the Securities and Exchange Commission on March 1, 2022

As filed with the Securities and Exchange Commission on March 1, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 INOVIO PHARMACEUTICALS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC.

Resolutions adopted by the Board of Directors Ratifying Option

Exhibit 99.1 Inovio Pharmaceuticals, Inc. Resolutions of the Board of Directors Ratification of Equity Awards Made By CEO Approved and adopted: February 24, 2022 Ratification of the Grant of Certain Stock Options and Restricted Stock Units WHEREAS, pursuant to Section 157(c) of the General Corporation Law of the State of Delaware ("DGCL"), a board of directors may, by a resolution, authorize an of

Subsidiaries of the registrant (filed herewith).

EX-21.1 2 ino-12312021x10kex211.htm EX-21.1 Exhibit 21.1 INOVIO PHARMACEUTICALS, INC. Subsidiaries Subsidiary Name(1) Jurisdiction of Organization Inovio Asia, LLC South Korea

INO / Inovio Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Inovio Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 45773H201 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is

BofA Securities, Inc., RBC Capital Markets, LLC and Oppenheimer & Co. Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrants Form 10-Q quarterly report for the quarter ended September 30, 2021 filed on November 9, 2021).

Exhibit 10.1 EXECUTION VERSION Inovio Pharamceuticals, Inc. Common Stock, $0.001 par value ATM EQUITY OFFERINGSM SALES AGREEMENT November 9, 2021 BofA Securities, Inc. RBC Capital Markets, LLC Oppenheimer & Co. Inc. c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o RBC Capital Markets, LLC Brookfield Place 200 Vesey Street, 8th Floor New York, New York 10281 c/o Oppenheimer &

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be registered Maximum Offering Price Per Share Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.001 par value (1) (1) $300,000

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252256 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be registered Maximum Offering Price Per Share Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.001 par value (1) (1) $300,000,000 $27,810 (1) An indeterminate number of shares of common stock as s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICA

Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 Inovio Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 Inovio Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 Inovio Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, I

Amended and Restated Collaboration and License Agreement dated June 7, 2021 between Inovio Pharmaceuticals, Inc. and Advaccine Biopharmaceuticals Suzhou Co., Ltd. (incorporated by reference to Exhibit 10.1 as filed with the registrants Form 10-Q quarterly report for the quarter ended June 30, 2021 filed on August 9, 2021).

Exhibit 10.1 AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT This Amended and Restated Collaboration and License Agreement (the ?Agreement?) is entered into as of June 7, 2021 (the ?Effective Date?) by and between Inovio Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 60 W. Germantown Pike, Suite 110, Plymouth Meetin

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 Inovio Pharmaceuticals, Inc.

* * * *

Exhibit 99.1 INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800 Phase 3 efficacy trial planned to commence this summer in areas of the world underserved by vaccines News follows recently announced Phase 2 data, which showed INO-4800 to be well-tolerated and immunogenic in all age groups PLYMOUTH MEETING, Pa., June 8, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Inovio Pharmaceuticals

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Inovio Pharmaceuticals, Inc.

INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors Dr. Dansey, Seagen’s Chief Medical Officer, brings extensive expertise in immuno-oncology and drug development Appointment of industry leader in drug development expands th

Exhibit 99.1 INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors Dr. Dansey, Seagen?s Chief Medical Officer, brings extensive expertise in immuno-oncology and drug development Appointment of industry leader in drug development expands the Board?s diverse industry, clinical development, research and commercialization expertise PLYMOUTH MEETING, PA ? May 17, 2021 ? INOVIO (

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS,

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or Trial achieved primary and secondary

Exhibit 99.2 INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18 Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 Inovio Pharmaceuticals, Inc.

Subsidiaries of the registrant (filed herewith).

Exhibit 21.1 INOVIO PHARMACEUTICALS, INC. Subsidiaries Subsidiary Name(1) Jurisdiction of Organization Inovio Asia, LLC South Korea

INOVIO Reports Fourth Quarter 2020 And Year-End Financial Results Investor Call Today at 4:30 PM ET

EX-99.1 Exhibit 99.1 INOVIO Reports Fourth Quarter 2020 And Year-End Financial Results Investor Call Today at 4:30 PM ET PLYMOUTH MEETING, PA – March 1, 2021 – INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results

- S-8

As filed with the Securities and Exchange Commission on March 1, 2021 Registration No.

Collaboration and License Agreement dated December 31, 2020 between Inovio Pharmaceuticals, Inc. and Advaccine Biopharmaceuticals Suzhou Co., Ltd. (filed herewith).

Exhibit 10.14 EXECUTION COPY COLLABORATION AND LICENSE AGREEMENT This Collaboration and License Agreement (the ?Agreement?) is entered into as of December 31, 2020 (the ?Effective Date?) by and between Inovio Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 60 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462 USA (?Ino

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inovio Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 45773H201 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Inovio Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 45773H201 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inovio Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 45773H201 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat

INOVIO Announces Pricing of Public Offering of Common Stock

EX-99.2 Exhibit 99.2 INOVIO Announces Pricing of Public Offering of Common Stock PLYMOUTH MEETING, Pa., January 20, 2021 (Globe Newswire) — INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the

INOVIO Announces Proposed Public Offering of Common Stock

EX-99.1 Exhibit 99.1 INOVIO Announces Proposed Public Offering of Common Stock PLYMOUTH MEETING, Pa., January 20, 2021 (Globe Newswire) — INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced that

Underwriting Agreement, dated January 20, 2021, by and among the Company and the Representatives of the several Underwriters named therein.

EX-1.1 Exhibit 1.1 Execution Version INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 17,700,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: January 20, 2021 INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 17,700,000 Shares of Common Stock UNDERWRITING AGREEMENT January 20, 2021 BofA Securities, Inc. Jefferies LLC as Representatives of the several Underwriters c/o BofA Securiti

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be registered(1) Maximum Offering Price Per Share Maximum Aggregate Offering Price Amount of Registration Fee(2)(3) Common Stock, $0.001 par value 20,355,000

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252256 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be registered(1) Maximum Offering Price Per Share Maximum Aggregate Offering Price Amount of Registration Fee(2)(3) Common Stock, $0.001 par value 20,355,000 $8.50 $173,017,500.00 $18,876.21 (1) Assumes exercise in full of

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2021 Inovio Pharmaceuticals, Inc.

Form S-3

S-3ASR 1 d110733ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on January 20, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Inovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0969592 (State or ot

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

EX-99.1 Exhibit 99.1 In the preliminary prospectus supplement to be used in connection with a proposed public offering of shares of its common stock by Inovio Pharmaceuticals, Inc. (the “Company”), the Company provided the following updates or supplements to the description of certain aspects of the Company’s business, certain legal proceedings and certain risk factors provided in the Company’s pr

Subject to Completion Preliminary Prospectus Supplement dated January 20, 2021

424B5 1 d113891d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252256 The information in this prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state or other jurisdiction where the o

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2021 Inovio Pharmaceuticals, Inc.

INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China Partnership Adds Asian Manufacturing Resource to INOVIO’s Global Manufacturing Consortium for INO-4800 INO-4800 Phase 2 Tr

EX-99.1 Exhibit 99.1 INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China Partnership Adds Asian Manufacturing Resource to INOVIO’s Global Manufacturing Consortium for INO-4800 INO-4800 Phase 2 Trial Fully Enrolled in China PLYMOUTH MEETING, Pa. and SUZHOU, China, Jan. 4, 2021 /PRNewswire/ – INOVIO (NASDAQ: INO), a biotechn

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2020 Inovio Pharmaceuticals, Inc.

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 Inovio Pharmaceuticals, Inc.

INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense

EX-99.1 Exhibit 99.1 INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense PLYMOUTH MEETING, PA – November 16, 2020 – INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICA

Termination of a Material Definitive Agreement - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2020 Inovio Pharmaceuticals, Inc.

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2020 Inovio Pharmaceuticals, Inc.

INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of COVID-19 Vaccine Candidate INO-4800

EX-99.1 Exhibit 99.1 INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of COVID-19 Vaccine Candidate INO-4800 PLYMOUTH MEETING, PA – September 28, 2020 – INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced that the U.S. Food and Drug Administration

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2020 Inovio Pharmaceuticals, Inc.

Award Agreement dated June 18, 2020 between Inovio Pharmaceuticals, Inc. and Natick Contracting Division (incorporated by reference to Exhibit 10.2 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2020 filed on August 10, 2020).

Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. AWARD/CONTRACT 1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700) RATING PAGE OF PAGES 1 [***] 2. CONTRACT (Proc. [***].

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, I

Other Transaction Authority For Prototype Agreement dated June 22, 2020 between Inovio Pharmaceuticals, Inc. and Natick Contracting Division (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2020 filed on August 10, 2020).

Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. OTHER TRANSACTION AUTHORITY FOR PROTOTYPE AGREEMENT BETWEEN Inovio Pharmaceuticals, Inc. (Awardee) 660 W Germantown Pike Ste 11

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 Inovio Pharmaceuticals, Inc.

INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA® 3PSP Smart Device and Procurement of CELLECTRA® 2000 for COVID-19 DNA Vaccine

EX-99.1 Exhibit 99.1 INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA® 3PSP Smart Device and Procurement of CELLECTRA® 2000 for COVID-19 DNA Vaccine • U.S. Government will support the scale-up of INOVIO’s proprietary intradermal DNA delivery device CELLECTRA® 3PSP to deliver INOVIO’s COVID-19 vaccine • INOVIO to report on interim US Phase 1

Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2020 Inovio Pharmaceuticals, Inc.

Submission of Matters to a Vote of Security Holders

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2020 Inovio Pharmaceuticals, Inc.

Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 Inovio Pharmaceuticals, Inc.

Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-237172 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 31, 2020) $100,000,000 Common Stock We have previously entered into an At-the-Market Equity Offering Sales Agreement, or the Sales Agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, relating to shares of our common stock offered by this prospectus

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS,

-

CORRESP Brian F. Leaf (703) 456-8053 [email protected] VIA EDGAR April 24, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Tracey McKoy Terence O’Brien Re: Inovio Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2019 File No. 001-14888 Filed March 12, 2020 Ladies and Gentlemen: O

INO / Inovio Pharmaceuticals, Inc. DEFA14A - - DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2020 Inovio Pharmaceuticals, Inc.

At-The-Market Equity Offering Sales Agreement dated April 3, 2020 between Inovio Pharmaceuticals, Inc. and Stifel, Nicolaus & Company, Incorporated.

EX-1.1 Exhibit 1.1 INOVIO PHARMACEUTICALS, INC. Common Stock ($0.001 par value per share) AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT April 3, 2020 STIFEL, NICOLAUS & COMPANY, INCORPORATED One South Street, 15th Floor Baltimore, Maryland 21202 Ladies and Gentlemen: Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, t

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

8-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2020 Inovio Pharmaceuticals, Inc.

Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-237172 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 31, 2020) $150,000,000 Common Stock We have entered into an At-the-Market Equity Offering Sales Agreement, or the Sales Agreement, with Stifel, Nicolaus & Company, Incorporated, or Stifel, relating to shares of our common stock offered by this prospectus supplement

definitive proxy statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin

-

CORRESP March 27, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

Form of Debt Securities Warrant Agreement and Warrant Certificate.

EX-4.8 EXHIBIT 4.8 INOVIO PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF 1 INOVIO PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between INOVIO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organi

Form S-3

S-3 Table of Contents As filed with the Securities and Exchange Commission on March 13, 2020 Registration No.

Form of Indenture, between the Registrant and one or more trustees to be named.

EX-4.4 EXHIBIT 4.4 INOVIO PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certi

Form of Common Stock Warrant Agreement and Warrant Certificate.

EX-4.6 EXHIBIT 4.6 INOVIO PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF 1 INOVIO PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between INOVIO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and e

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

EX-4.7 EXHIBIT 4.7 INOVIO PHARMACEUTICALS, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF 1 INOVIO PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between INOVIO PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organi

Subsidiaries of the registrant (filed herewith).

Exhibit 21.1 INOVIO PHARMACEUTICALS, INC. Subsidiaries Subsidiary Name(1) Jurisdiction of Organization Genetronics, Inc. California VGX Pharmaceuticals, LLC Delaware VGX Animal Health, Inc. Delaware GENEOS Therapeutics, Inc. Delaware

Exhibit 4.3

Exhibit 4.9 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description summarizes selected information regarding our capital stock, as well as relevant provisions of: (i) our certificate of incorporation; (ii) our amended and restated bylaws; and (iii) the General Corporation Law of the State of Delaware, or the DGC

Employment Agreement dated as of March 4, 2019 between Inovio Pharmaceuticals, Inc. and Laurent M. Humeau (incorporated by reference to Exhibit 10.27 of the registrant's Form 10-K annual report for the year ended December 31, 2019 filed on March 12, 2020).

Exhibit 10.27 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), dated as of March 4, 2019 is made by and between Inovio Pharmaceuticals, Inc., a Delaware corporation having offices at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462 (the “Company”), and Laurent Michel Paul Francois Humeau, Ph.D.(Executive). RECITALS WHEREAS, the Company and Executive entered into an Em

Employment Agreement dated March 8, 2019 between Inovio Pharmaceuticals, Inc. and Jacqueline E. Shea (incorporated by reference to Exhibit 10.26 of the registrant's Form 10-K annual report for the year ended December 31, 2019 filed on March 12, 2020).

Exhibit 10.26 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), dated as of March 8, 2019 is made by and between Inovio Pharmaceuticals, Inc., a Delaware corporation having offices at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462 (the “Company”), and Jacqueline E. Shea, Ph.D. (“Executive”). RECITALS WHEREAS, the Company desires to employee Executive and to have the

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC.

Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-225233 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 8, 2018) $50,000,000 Common Stock We have entered into a second amendment to the At-the-Market Equity Offering Sales Agreement dated May 25, 2018 with Stifel, Nicolaus & Company, Incorporated, or Stifel, as amended on February 7, 2020, relating to shares of our common stoc

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2020 Inovio Pharmaceuticals, Inc.

Amendment No. 2 to the At-The-Market Equity Offering Sales Agreement dated March 9, 2020 between Inovio Pharmaceuticals, Inc. and Stifel, Nicolaus & Company, Incorporated.

EX-1.3 Exhibit 1.3 INOVIO PHARMACEUTICALS, INC. AMENDMENT NO. 2 TO THE AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT March 9, 2020 STIFEL, NICOLAUS & COMPANY, INCORPORATED One South Street, 15th Floor Baltimore, Maryland 21202 Ladies and Gentlemen: Reference is made to the At-The-Market Equity Offering Sales Agreement, dated as of May 25, 2018 (the “Original Sales Agreement”) between Stifel, Nicol

INO / Inovio Pharmaceuticals, Inc. / Nikko Asset Management Americas, Inc. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Inovio Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 45773H201 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig

INO / Inovio Pharmaceuticals, Inc. / Sumitomo Mitsui Trust Holdings, Inc. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* Inovio Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 45773H201 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design

INO / Inovio Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Inovio Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 45773H201 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b

INO / Inovio Pharmaceuticals, Inc. CORRESP - -

CORRESP February 10, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

Common Stock

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-225233 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 8, 2018) $100,000,000 Common Stock We have entered into an amendment to the At-the-Market Equity Offering Sales Agreement dated May 25, 2018 with Stifel, Nicolaus & Company, Incorporated, or Stifel, relating to shares of our common stock offered by this prospectus su

Amendment No. 1 to the At-The-Market Equity Offering Sales Agreement dated February 7, 2020 between Inovio Pharmaceuticals, Inc. and Stifel, Nicolaus & Company, Incorporated.

EX-1.2 Exhibit 1.2 INOVIO PHARMACEUTICALS, INC. AMENDMENT NO. 1 TO THE AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT February 7, 2020 STIFEL, NICOLAUS & COMPANY, INCORPORATED One South Street, 15th Floor Baltimore, Maryland 21202 Ladies and Gentlemen: Reference is made to the At-The-Market Equity Offering Sales Agreement, dated as of May 25, 2018 (the “Sales Agreement”) between Stifel, Nicolaus &

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2020 Inovio Pharmaceuticals, Inc.

INO / Inovio Pharmaceuticals, Inc. S-3 - - S-3

S-3 Table of Contents As filed with the Securities and Exchange Commission on January 31, 2020 Registration No.

INO / Inovio Pharmaceuticals, Inc. S-8 - - S-8

S-8 As filed with the Securities and Exchange Commission on January 31, 2020 Registration No.

Inovio Welcomes Biotech Leader To its Board of Directors Inovio also announces retirement of long-serving board member

EX-99.1 Exhibit 99.1 CONTACTS: Investors: Ben Matone, 484-362-0076, [email protected] Media: Jeff Richardson, 267-440-4211, [email protected] Inovio Welcomes Biotech Leader To its Board of Directors Inovio also announces retirement of long-serving board member PLYMOUTH MEETING, PA – January 15, 2020 – Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the appointment of Jay Shepard

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2020 Inovio Pharmaceuticals, Inc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2019 Inovio Pharmaceuticals, Inc.

Convertible Bonds Subscription Agreement, dated December 26, 2019, by and between the registrant and the Purchaser named therein (incorporated by reference to Exhibit 4.1 to the registrant’s current report on Form 8-K filed with the SEC on January 2, 2020).

EX-4.1 Exhibit 4.1 Execution Version Dated December 26, 2019 CONVERTIBLE BONDS SUBSCRIPTION AGREEMENT between INOVIO PHARMACEUTICALS, INC. - Company - and The Overseas Growth Fund I - Investor - THIS CONVERTIBLE BONDS SUBSCRIPTION AGREEMENT (this “Agreement”) dated December 26, 2019 is made by and between: (1) INOVIO PHARMACEUTICALS, INC., a Delaware corporation, having its registered office in th

Registration Rights Agreement, dated December 26, 2019, by and between the registrant and the Purchaser named therein (incorporated by reference to Exhibit 10.1 to the registrant’s current report on Form 8-K filed with the SEC on January 2, 2020).

EX-10.1 Exhibit 10.1 Inovio Pharmaceuticals, Inc. KRW4,700,000,000 1.00% Convertible Bonds due 2024 Registration Rights Agreement December 26, 2019 Each of the Holders listed on Schedule A hereto Ladies and Gentlemen: Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to you, its 1.00% Convertible Bonds due 2024 (the “Bonds”), in the amounts and upon t

November 12, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICA

August 8, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, I

Convertible Bonds Subscription Agreement, dated July 31, 2019, by and among the registrant and the Purchasers named therein (incorporated by reference to Exhibit 4.1 to the registrant’s current report on Form 8-K filed with the SEC on August 6, 2019).

EX-4.1 Exhibit 4.1 EXECUTION VERSION Dated July 31, 2019 CONVERTIBLE BONDS SUBSCRIPTION AGREEMENT between INOVIO PHARMACEUTICALS, INC. - Company - and KIP RE-UP FUND KIP ACE FUND (17) KIP BEYOND FUND (17) KIP CORE FUND (17) KIP DREAM FUND (17) KIP ESSENCE FUND (17) KIP FUTURE FUND (17) KIP GROWTH FUND (17) KIP HIGH FUND (17) KIP IMPACT FUND (17) KIP JOINT FUND (17) KIP KEY FUND (17) SAMSUNG SECURI

CONTACTS: Investors: Ben Matone, 484-362-0076, [email protected] Media: Jeff Richardson, 267-440-4211, [email protected] Inovio Closes $15 Million Private Placement of Convertible Bonds to Institutional Investors in Korea Inovio Intends to P

EX-99.2 Exhibit 99.2 CONTACTS: Investors: Ben Matone, 484-362-0076, [email protected] Media: Jeff Richardson, 267-440-4211, [email protected] Inovio Closes $15 Million Private Placement of Convertible Bonds to Institutional Investors in Korea Inovio Intends to Pursue Secondary Listing on Korea Exchange (KRX) PLYMOUTH MEETING, Pa., USA, August 6, 2019 – Inovio Pharmaceuticals, Inc. (NASDAQ

Inovio Pharmaceuticals, Inc. KRW18,000,000 1.00% Convertible Bonds due 2024 Registration Rights Agreement

EX-99.1 Exhibit 99.1 EXECUTION VERSION Inovio Pharmaceuticals, Inc. KRW18,000,000 1.00% Convertible Bonds due 2024 Registration Rights Agreement July 31, 2019 Each of the Holders listed on Schedule A hereto Ladies and Gentlemen: Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to you, its 1.00% Convertible Bonds due 2024 (the “Bonds”), in the amounts

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2019 Inovio Pharmaceuticals, Inc.

Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates Company Cuts Selected Early-Stage R&D Programs, Burn-Rate by 25%, and Staff by 28% Management to Host Conference Call on July 17 at 8:00 AM EDT

EX-99.1 Exhibit 99.1 CONTACTS: Investors: Ben Matone, 484-362-0076, [email protected] Media: Jeff Richardson, 267-440-4211, [email protected] Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates Company Cuts Selected Early-Stage R&D Programs, Burn-Rate by 25%, and Staff by 28% Management to Host Conference Call on July 17 at 8:00 AM EDT PLYMOUTH MEETING, Pa.

Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2019 Inovio Pharmaceuticals, Inc.

Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2019 Inovio Pharmaceuticals, Inc.

INO / Inovio Pharmaceuticals, Inc. S-8 - - S-8

S-8 1 d664451ds8.htm S-8 As filed with the Securities and Exchange Commission on May 31, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Inovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0969592 (State or other jurisdiction of incorporati

Other Events

8-K 1 d752204d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2019 Inovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14888 33-0969592 (State or other jurisdiction of i

Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2019 Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. 2016 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the registrant’s current report on Form 8-K filed on May 10, 2019).

EX-10.1 Exhibit 10.1 INOVIO PHARMACEUTICALS, INC. 2016 OMNIBUS INCENTIVE PLAN Adopted by the Board of Directors: March 9, 2016 Approved by Stockholders: May 13, 2016 Amended by the Board of Directors: March 21, 2019 Approved by Stockholders: May 8, 2019 INOVIO PHARMACEUTICALS, INC. 2016 OMNIBUS INCENTIVE PLAN ARTICLE I PURPOSE AND ADOPTION OF THE PLAN 1.1 Purpose. The purpose of the Inovio Pharmac

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2019 Inovio Pharmaceuticals, Inc.

Separation Agreement dated March 26, 2019 between Inovio Pharmaceuticals, Inc. and Mark L. Bagarazzi (incorporated by reference to Exhibit 10.1 to the registrant's Form 10-Q quarterly report for the quarter ended March 31, 2019 filed on May 9, 2019).

Exhibit 10.1 March 26, 2019 Mark Bagarazzi Re: Separation Agreement Dear Mark: This letter sets forth the substance of the separation agreement (the “Agreement”) which Inovio Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. In accordance with Section 7(c) of your employment agreement, dated as of December 10, 2009 (as amended, the “Emplo

May 9, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS,

Proxy Statement

DEF 14A 1 ino-2019xproxy.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as p

CONTACTS: Investors: Ben Matone, Inovio, 484-362-0076, [email protected] Media: Jeff Richardson, Inovio, 267-440-4211, [email protected] Inovio Appoints Global Commercial Leader to its Board of Directors

EX-99.1 Exhibit 99.1 CONTACTS: Investors: Ben Matone, Inovio, 484-362-0076, [email protected] Media: Jeff Richardson, Inovio, 267-440-4211, [email protected] Inovio Appoints Global Commercial Leader to its Board of Directors PLYMOUTH MEETING, PA – March 25, 2019 – Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Dr. Ann C. Miller to its Board of Directors. Dr.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2019 Inovio Pharmaceuticals, Inc.

INO / Inovio Pharmaceuticals, Inc. S-8

S-8 As filed with the Securities and Exchange Commission on March 15, 2019 Registration No.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 d630823d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2019 Inovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-14888 33-0969592 (State or other jurisdictio

Inovio Appoints Chief Operating Officer; Announces Strategic Management Changes

EX-99.1 Exhibit 99.1 CONTACTS: Investors: Ben Matone, Inovio, 484-362-0076, [email protected] Media: Jeff Richardson, Inovio, 267-440-4211, [email protected] Inovio Appoints Chief Operating Officer; Announces Strategic Management Changes PLYMOUTH MEETING, PA – March 12, 2019 – Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Jacqueline E. Shea, PhD, as Inovio’

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC.

Consulting Agreement dated February 21, 2019 by and between Inovio Pharmaceuticals, Inc. and Dr. Niranjan Sardesai (filed herewith).

Exhibit 10.43 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is made by and between Inovio Pharmaceuticals, Inc. (“Inovio”), a Delaware corporation, with a place of business at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462 and Niranjan Y. Sardesai, Ph.D. (“Consultant”), with a place of business at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462. This

Subsidiaries of the registrant.

Exhibit 21.1 INOVIO PHARMACEUTICALS, INC. Subsidiaries Subsidiary Name(1) Jurisdiction of Organization Genetronics, Inc. California VGX Pharmaceuticals, LLC Delaware VGX Animal Health, Inc. Delaware GENEOS Therapeutics, Inc. Delaware

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2019 Inovio Pharmaceuticals, Inc.